Medicine put to the test

The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Fostamatinib in chronic immune thrombocytopenia: no comparison – added benefit not proven

2020-10-01 The manufacturer conducted no direct or indirect comparison of its drug with an appropriate comparator therapy (eltrombopag or romiplostim).

read more Link to \Fostamatinib in chronic immune thrombocytopenia: no comparison – added benefit not proven\""

Pancreatic surgery: lower mortality with larger case volumes

2020-09-28 The survival probabilities are higher in hospitals where complex pancreatic surgery is performed more frequently.

read more Link to \Pancreatic surgery: lower mortality with larger case volumes\""

Talazoparib in breast cancer: hint of considerable added benefit

2020-09-01 Advantages in health-related quality of life, symptoms and side effects outweigh the few disadvantages. Data for the time after progression are missing, however.

read more Link to \Talazoparib in breast cancer: hint of considerable added benefit\""

Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit

2020-08-17 For the first time, new data from the PROSPER study show an advantage in overall survival that outweighs the disadvantages in some side effects.

read more Link to \Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit\""

Darolutamide in prostate cancer: indication of considerable added benefit

2020-08-03 The advantages in the outcome categories of mortality, morbidity and health-related quality of life are not accompanied by disadvantages.

read more Link to \Darolutamide in prostate cancer: indication of considerable added benefit\""

Network meta-analyses: no compensation for weak evidence

2020-07-07 Numerous biologics for the treatment of rheumatoid arthritis have been available for several years. What are the advantages and disadvantages of the individual drugs in combination with methotrexate c…

read more Link to \Network meta-analyses: no compensation for weak evidence\""

Diabetic nephropathy: Study results on proteomic analysis do not show benefit

2020-07-06 First study on a treatment strategy using a proteomic analysis does not clarify which therapeutic consequence of the test could offer a benefit for people with diabetes and high blood pressure.

read more Link to \Diabetic nephropathy: Study results on proteomic analysis do not show benefit\""

Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority

2020-07-01 New antibiotic broadens the treatment options for severe infections and resistances. However, there is no evidence of advantages or disadvantages in comparison with other antibiotics.

read more Link to \Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority\""

Non-invasive diagnostic procedures for suspected CHD: search reveals informative evidence

2020-06-30 Informative study results are available on diagnostic procedures using computed tomography angiography (CTA) and magnetic resonance imaging (MRI) for suspected coronary heart disease (CHD).

read more Link to \Non-invasive diagnostic procedures for suspected CHD: search reveals informative evidence\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

There are no actual comments.


Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Tezacaftor / ivacaftor (Symkevi) for the treatment of cystic fibrosis

The fixed-dose combination of tezacaftor / ivacaftor (trade name: Symkevi) has been approved in Germany since October 2018 for the treatment of cystic fibrosis in people aged 12 and over.   read more (Link to \Tezacaftor / ivacaftor (Symkevi) for the treatment of cystic fibrosis\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close